ArticleCancer causes & control : CCC2025
COVID-19 impacts on the breast cancer care pathway among systemically marginalized communities in Ontario.
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHealthcare system pauses occurred worldwide due to COVID-19, and may have worsened pre-existing disparities in breast cancer care. In this population-based, retrospective cohort study, we investigated indicators of breast cancer care (i.e., adherence to screening guidelines, early vs. late-stage diagnosis, and mastectomy vs. breast-conserving surgery) before and after COVID-19 lockdowns in Ontario, with an emphasis on immigrant women.
methodsWe had three binary outcomes and corresponding cohorts, and each outcome/cohort was ascertained relative to two time periods: April 1, 2018-March 31, 2020 ("pre-pandemic") and April 1, 2020-March 31, 2022 ("pandemic"): i) up to date on screening, ii) early vs late stage of breast cancer diagnosis, and iii) mastectomy vs breast-conserving surgery at any time after diagnosis for women who were diagnosed at stages I-III during each two-year time period. We conducted descriptive analyses, and used logistic regression, both unadjusted and adjusted, to determine odds ratios for our dichotomous outcomes.
resultsBreast cancer screening rates dropped from 59.4% to 51.0%, and the number of women diagnosed dropped from 18,821 to 14,269, in the pre-pandemic vs pandemic period. In multivariable analyses, screening significantly dropped (AOR = 0.69 [95% CI (0.69-0.69)]), there was no significant difference for diagnostic stage (AOR = 0.99 [95% CI (0.92-1.05)]), and the use of mastectomy vs breast-conserving surgery was higher in the pandemic period (AOR = 1.14 [95% CI (1.08-1.20)]). Women from the Caribbean had lower odds of early-stage diagnosis in the pre-pandemic period despite a screening advantage.
conclusionFuture work should further explore the reasons for these findings and potential system-level solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.